3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
14
Phase 3
3
Phase 1
3
Phase 4
2
Phase 2/3
2
Phase 1/2
2
Phase EARLY_PHASE1
1
Status
Terminated
1
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Dermatologic
3
Thoracic
1
Conditions
Melanoma
2
Melanoma, Cutaneous Malignant
1
Interventions
Dacarbazine
27
Nivolumab
26
pembrolizumab
22
Ipilimumab
20
3-ingenyl angelate
11
Interferon-alpha
10
Imiquimod
10
Temozolomide
9
trametinib
8
Vemurafenib
8
Photochemotherapy
8
Aminolevulinic Acid
8
methyl 5-aminolevulinate
7
dabrafenib
7
cemiplimab
7
aldesleukin
7
Introns
7
Surgical Procedures, Operative
6
Radiotherapy
6
Interferon alpha-2
6
Fluorouracil
6
Paclitaxel
5
Melphalan
5
Interleukin-2
5
Cisplatin
5
Chemotherapy, Adjuvant
5
talimogene laherparepvec
4
binimetinib
4
Specimen Handling
4
Opdualag
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
relatlimab
×
Dermatologic
×
Clear all
NCT05625399
2026-06-03
RELATIVITY-127
Bristol-Myers Squibb
Phase 3
Active not recruiting
579 enrolled
NCT06743126
2026-05-29
SUPRAME
Immatics US, Inc.
Phase 3
Recruiting
360 enrolled
NCT05002569
2026-01-08
RELATIVITY-098
Bristol-Myers Squibb
Phase 3
Terminated
1,093 enrolled
15 charts